文献速递腹部MRCTUS

LI-RADS 辅助特征诊断肝细胞癌的系统综述与证据整合

Diagnostic performance of liver imaging reporting and data system ancillary features for hepatocellular carcinoma: a systematic review and evidence synthesis.
PubMed 文献 · Abdom Radiol (NY) · 2026-09-10

该系统综述纳入 2011–2024 年 101 篇研究,评估 LI-RADS 辅助特征(AFs)在 MRI、CT 和 CEUS 上优化 HCC 诊断的价值。MRI 证据最充分,识别出 14 个显著辅助特征;对 ≤3 cm 病灶单用指南推荐 AF 增量有限,联合 ≥4 个 AF 可显著提高敏感度 10.6–18.3% 而不明显损失特异度。CT 和 CEUS 证据有限且不一致,需进一步验证。

要点

  • MRI 是 LI-RADS AFs 证据最强的模态,识别出 14 个显著辅助特征。
  • ≤3 cm 病灶单用指南推荐 AF 增量有限,联合 ≥4 个 AF 可提高敏感度。
  • LR-M 病灶有 14 个 SAFs 有助于鉴别 HCC 与其他肝脏恶性肿瘤。

核心结论

  • LI-RADS 辅助特征在主要特征基础上可提高 HCC 诊断准确性,MRI 证据最稳健。
  • CT 和 CEUS 的辅助特征证据有限且不一致,需进一步验证。

研究设计与样本

  • 系统综述与证据整合,检索 PubMed 和 Embase 2011–2024 年文献,共纳入 101 篇研究。
  • 研究模态分布:MRI 占 91.1%(92/101),CT 占 21.8%(22/101),CEUS 占 9.9%(10/101)。
  • 显著辅助特征(SAFs)定义为在至少一项纳入研究中显示对 HCC 诊断或 LI-RADS 诊断性能有统计学显著贡献(p < 0.05)的特征,为综述特定描述框架而非官方 LI-RADS 分类。

诊断标准与关键数值

  • MRI 上 LI-RADS LR-1 至 LR-5 类别中识别出 14 个 SAFs,包括肝胆期低信号和弥散受限。
  • 对 ≤3 cm 病灶,应用单个指南推荐 AF 的增量价值有限;联合 ≥4 个 AFs 可使敏感度提高 10.6–18.3%,特异度无明显损失。
  • CEUS 上 LR-1 至 LR-5 观察中识别出 6 个 AFs,探索性标志物显示潜在增量价值,而两个官方 AFs 表现不一致。
  • 对 LR-M 病灶,14 个 SAFs 显著有助于鉴别 HCC 与其他肝脏恶性肿瘤(p < 0.05)。
  • 在治疗反应评估中,5 个 SAFs(其中 2 个为指南推荐)使诊断敏感度提高 3.2–42.8%,特异度无损失。

临床应用与阅片要点

  • 阅片时可关注 MRI 肝胆期低信号和弥散受限等 SAFs,联合多个 AFs 可提高小 HCC 检出敏感度。
  • 对 ≤3 cm 病灶,不应仅依赖单个指南推荐 AF,需结合主要特征和多个 AFs 综合判断。
  • LR-M 病灶可借助 14 个 SAFs 鉴别 HCC 与其他肝脏恶性肿瘤,避免误诊。
  • 治疗反应评估中可参考 5 个 SAFs(含 2 个指南推荐)提高诊断敏感度。
  • CT 和 CEUS 的 AFs 证据尚不充分,解读时需谨慎,不宜照搬 MRI 证据。

局限性

  • CT 和 CEUS 研究数量有限(分别为 22 篇和 10 篇),证据有限且不一致。
  • MRI 研究占绝对多数(91.1%),其他模态证据代表性不足。
  • SAFs 为综述特定描述框架,非官方 LI-RADS 分类,可能影响结果外推。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

英文原文(摘要)· 点击展开

OBJECTIVE: To systematically review and evaluate the evidence supporting the role of Liver Imaging Reporting and Data System (LI-RADS) ancillary features (AFs) in optimizing hepatocellular carcinoma (HCC) diagnosis across magnetic resonance imaging (MRI), computed tomography (CT), and contrast-enhanced ultrasound (CEUS) modalities, with a focus on their incremental value in specific clinical scenarios.

METHODS: A comprehensive literature search was performed across PubMed and Embase from 2011 to 2024 to identify studies on LI-RADS AFs. Significant ancillary features (SAFs)-a review-specific descriptive framework rather than an official LI-RADS category-were defined as features demonstrating a statistically significant contribution to HCC diagnosis or LI-RADS diagnostic performance in at least one included study (p < 0.05).

RESULTS: A total of 101 articles were included. In terms of imaging modality distribution, MRI was predominant (91.1%, 92/101), while CT (21.8%, 22/101) and CEUS (9.9%, 10/101) studies were relatively limited. For LI-RADS categories LR-1 to LR-5, fourteen SAFs were identified on MRI (e.g., hepatobiliary phase hypointensity, diffusion restriction). For lesions ≤ 3 cm, the incremental value of applying a single guideline-recommended AF was marginal. In contrast, applying combinations of ≥ 4 AFs significantly improved sensitivity by 10.6-18.3% without a significant loss of specificity. Evidence for CT-based AFs was limited and inconsistent. For CEUS LR-1 to LR-5 observations, six AFs were identified, with exploratory markers showing potential incremental value, whereas the two official AFs showed inconsistent performance. For LR-M lesions, 14 SAFs significantly contributed to differentiating HCC from other hepatic malignancies (p < 0.05). In treatment response assessment (TRA), five SAFs-two of which are guideline-recommended-improved diagnostic sensitivity by 3.2-42.8% without loss of specificity.

CONCLUSION: LI-RADS AFs enhance HCC diagnostic accuracy when complementing major features, with the most robust evidence supporting MRI-based AFs. In contrast, AFs based on CT and CEUS require further validation.

来源:Abdom Radiol (NY),查看原文。版权归原作者所有。

引用

  1. Chang X, Wang Z, Fan F, et al. Diagnostic performance of liver imaging reporting and data system ancillary features for hepatocellular carcinoma: a systematic review and evidence synthesis. Abdom Radiol (NY). 2026. PMID: 42720760. doi:10.1007/s00261-026-05734-4

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。